{"ticker": {"uuid": "f8af74e2-0372-465c-b306-2b47187ca083", "symbol": "NOVOBN", "name": "Novo Nordisk A/S", "exchange": "MEX", "country": "MX", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:29:11+00:00", "published_display": "12 Aug 2026 17:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.389, "duplicate_count": 1, "topics": ["Downgrade", "Earnings", "Pharma"]}, {"title": "European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading", "summary": "European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:11:23+00:00", "published_display": "12 Aug 2026 15:11", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.382, "duplicate_count": 1, "topics": []}, {"title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "summary": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:10:00+00:00", "published_display": "12 Aug 2026 15:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.478, "duplicate_count": 1, "topics": ["Diabetes", "Earnings", "Fourth Quarter", "Guidance", "Obesity", "Pharma"]}, {"title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "summary": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:03:00+00:00", "published_display": "12 Aug 2026 15:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.263, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Obesity", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "Here Are Wednesday\u2019s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More", "summary": "Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind", "url": "https://finance.yahoo.com/markets/stocks/articles/wednesday-top-wall-street-analyst-115341914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:53:41+00:00", "published_display": "12 Aug 2026 11:53", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.373, "duplicate_count": 1, "topics": ["Crypto", "Earnings", "Price Target", "Price Target", "Upgrade Downgrade"]}, {"title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. ", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:07:32+00:00", "published_display": "11 Aug 2026 19:07", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.475, "duplicate_count": 1, "topics": ["Fda Approval", "Obesity", "Pharma", "Regulation"]}, {"title": "European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading", "summary": "European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/stocks/articles/european-equities-traded-us-american-152616420.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:26:16+00:00", "published_display": "11 Aug 2026 15:26", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.322, "duplicate_count": 1, "topics": []}, {"title": "Lilly Takes Its Weight-Loss Pill Battle Overseas", "summary": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo", "url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:12:41+00:00", "published_display": "11 Aug 2026 15:12", "sentiment": "positive", "sentiment_pct": 57, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.462, "duplicate_count": 1, "topics": ["Fda Approval", "Healthcare", "Pharma", "UK Approval"]}, {"title": "Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?", "summary": "The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:44:16+00:00", "published_display": "11 Aug 2026 12:44", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.454, "duplicate_count": 1, "topics": ["Clinical Trials", "Financial Results", "Lawsuit", "Net Income", "Obesity Treatment", "Pharma"]}, {"title": "Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery", "summary": "Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica", "url": "https://finance.yahoo.com/healthcare/articles/cloud-ai-today-novo-nordisk-123802779.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:38:02+00:00", "published_display": "11 Aug 2026 12:38", "sentiment": "neutral", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.241, "duplicate_count": 1, "topics": ["AI", "Cloud", "Earnings"]}, {"title": "NVO Crosses Above Average Analyst Target", "summary": "In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst ", "url": "https://www.nasdaq.com/articles/nvo-crosses-above-average-analyst-target-0", "source_name": "nasdaq.com", "published_at": "2026-08-11T11:43:35+00:00", "published_display": "11 Aug 2026 11:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.314, "duplicate_count": 1, "topics": ["Etfs", "Markets", "Price Target", "Price Target", "Ratings", "Stocks"]}, {"title": "Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America\u2019s New Drug Manufacturing Policies?", "summary": "For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-222158536.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:21:58+00:00", "published_display": "10 Aug 2026 22:21", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.356, "duplicate_count": 1, "topics": ["Fda", "Manufacturing", "Obesity Drugs", "Pharma", "Revenue Growth", "Shareholder"]}, {"title": "Why Eli Lilly Topped the Market Today", "summary": "Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly \u203a Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight", "url": "https://www.nasdaq.com/articles/why-eli-lilly-topped-market-today", "source_name": "nasdaq.com", "published_at": "2026-08-10T22:13:52+00:00", "published_display": "10 Aug 2026 22:13", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.25, "duplicate_count": 1, "topics": ["Europe", "Markets", "Obesity Treatments", "Pharma", "Regulation"]}, {"title": "Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?", "summary": "The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthro", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-213923809.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T21:39:23+00:00", "published_display": "10 Aug 2026 21:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.23, "duplicate_count": 1, "topics": ["Manufacturing", "Obesity Market", "Pharma"]}, {"title": "Hims Stock Falls on Earnings. Why a Guidance Hike Isn\u2019t Enough.", "summary": "Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading", "url": "https://finance.yahoo.com/m/db700a16-f71a-30fb-9e7e-c325c0d84078/hims-stock-falls-on-earnings..html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T21:12:00+00:00", "published_display": "10 Aug 2026 21:12", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.353, "duplicate_count": 1, "topics": ["Healthcare", "Restructuring"]}, {"title": "Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-rises-2-193507373.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T19:35:07+00:00", "published_display": "10 Aug 2026 19:35", "sentiment": "neutral", "sentiment_pct": 46, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.213, "duplicate_count": 1, "topics": ["Fda Approval", "Glp 1", "Obesity", "Pharma", "Revenue Outlook"]}, {"title": "European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments", "summary": "The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/stocks/articles/european-stocks-close-mixed-monday-153834840.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:38:34+00:00", "published_display": "10 Aug 2026 15:38", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.271, "duplicate_count": 1, "topics": []}, {"title": "This Biotech\u2019s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.", "summary": "New data show a single dose of AbCellera\u2019s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading", "url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:12:00+00:00", "published_display": "10 Aug 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.133, "duplicate_count": 1, "topics": []}, {"title": "Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock", "summary": "Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-rises-almost-7-post-131700150.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T13:17:00+00:00", "published_display": "10 Aug 2026 13:17", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.333, "duplicate_count": 1, "topics": ["Earnings", "Earnings Growth", "Earnings Per Share", "Obesity", "Oncology", "Patent Cliff"]}, {"title": "Is new time to buy weakness in Novo Nordisk stock? Bernstein answers", "summary": "", "url": "", "source_name": "Investing.com", "published_at": "2026-08-10T10:46:21+00:00", "published_display": "10 Aug 2026 10:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.178, "duplicate_count": 1, "topics": []}, {"title": "Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress", "summary": "Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients \u2013 -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 -- -- Company to host conference call and webcast t", "url": "https://finance.yahoo.com/healthcare/articles/veru-reports-fiscal-2026-third-103000378.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T10:30:00+00:00", "published_display": "10 Aug 2026 10:30", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.327, "duplicate_count": 1, "topics": ["Biopharmaceuticals", "Clinical Trials", "Financial Results", "Fourth Quarter", "Obesity", "Operating Income"]}, {"title": "Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date", "summary": "(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-holding-says-apitegromab-091940105.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T09:19:40+00:00", "published_display": "10 Aug 2026 09:19", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.259, "duplicate_count": 1, "topics": ["Biotech", "Fda Approval"]}, {"title": "Nvidia, Eli Lilly, and Disney Show It\u2019s Time to Back the Top Dogs", "summary": "Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading", "url": "https://finance.yahoo.com/m/bd14b29c-18a2-3bb0-930e-e50923390400/nvidia%2C-eli-lilly%2C-and-disney.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T05:00:00+00:00", "published_display": "10 Aug 2026 05:00", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.204, "duplicate_count": 1, "topics": []}, {"title": "Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients", "summary": "Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing, while providing home delivery and in-store pickup to streamline access. Amazon Pharmacy will begin enrollment for eligible patients after they add their insurance and Medicare information and their clinician ", "url": "https://finance.yahoo.com/healthcare/articles/ozempic-50-month-amazon-pharmacy-013108263.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T01:31:08+00:00", "published_display": "10 Aug 2026 01:31", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.306, "duplicate_count": 1, "topics": ["Digital Healthcare", "Pharmacy", "Real Estate", "Weight Loss"]}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "sentiment": "negative", "sentiment_pct": 43, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.28, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Earnings Per Share", "Guidance", "Healthcare", "M A"]}, {"title": "Top global stories this week: BP, SoftBank among notable names", "summary": "US stock indexes ended the week higher supported by a rally in mega-cap technology stocks, a rebound in Treasury securities and robust corporate earnings. By the end of the week, geopolitical tensions involving Iran pushed crude oil prices toward $78 per barrel, raising fears that higher energy costs could stoke inflation and delay central bank rate cuts. For the week, the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) rose 3% and 3.9%, while Dow (DJI [https://seekingalpha.com/symbol/DJI]) booked a 1.8% uptick. Across th", "url": "https://seekingalpha.com/news/4629627-top-global-stories-this-week-bp-softbank-among-notable-names?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:00:00+00:00", "published_display": "09 Aug 2026 13:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.252, "duplicate_count": 1, "topics": ["Acquisition", "Earnings", "Earnings News", "Guidance", "On The Move", "Semiconductors"]}, {"title": "Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-231020183.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T23:10:20+00:00", "published_display": "08 Aug 2026 23:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.165, "duplicate_count": 1, "topics": ["Balance Sheet", "Healthcare", "Patent Enforcement", "Pharma", "Share Price"]}, {"title": "Novo Nordisk A/S Q2 Earnings Call Highlights", "summary": "Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-q2-earnings-call-220350961.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T22:03:50+00:00", "published_display": "08 Aug 2026 22:03", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.251, "duplicate_count": 1, "topics": ["Cardiovascular", "Diabetes", "Earnings", "Obesity", "Pharmaceuticals"]}, {"title": "BofA points to the Eli Lilly market that could outsize the U.S.", "summary": "Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came out of the earnings call pointing to a different number. The bank thinks the obesity market outside the United States could eventually surpass U.S. sales of the same drugs. For anyone holding LLY or considering it, that international call is worth a closer look. Why Bank of America raised its Eli Lill", "url": "https://finance.yahoo.com/healthcare/articles/bofa-points-eli-lilly-market-183300957.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T18:33:00+00:00", "published_display": "08 Aug 2026 18:33", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.245, "duplicate_count": 1, "topics": ["Drug Development", "Earnings", "Earnings Estimate", "Obesity", "Pharma", "Price Target"]}, {"title": "Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets", "summary": "[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a", "url": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-08T17:12:36+00:00", "published_display": "08 Aug 2026 17:12", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.242, "duplicate_count": 1, "topics": ["AI", "Consensus Estimate", "Earnings", "Earnings Per Share", "Earnings Report", "Fourth Quarter"]}, {"title": "Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem", "summary": "Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. This new product could help Eli Lilly extend its lead over its biggest competitor in this space, Novo Nordisk (NYSE: NVO). Here's the rundown. Best-in-class efficacy In a phase 3 study, retatrutide posted an average ", "url": "https://finance.yahoo.com/healthcare/articles/eli-lillys-timing-fda-filing-225000821.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T22:50:00+00:00", "published_display": "07 Aug 2026 22:50", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.212, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Earnings Per Share", "Fda Approval", "Financial Results", "Pharma"]}, {"title": "Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date", "summary": "Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and under their guidance, will remove Catalent Indiana fill-finish facility from apitegromab BLA FDA review of second fill-finish facility progressing; Data package for FDA review of second fill-finish facility, as agreed to during March 2026 Type C meeting, has been submitted in advance of agreed up", "url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-announces-fda-review-202000956.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T20:20:00+00:00", "published_display": "07 Aug 2026 20:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.25, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Press Releases", "Rare Diseases", "Spinal Muscular Atrophy"]}, {"title": "Novo Nordisk Stock Rises After GLP-1 Antitrust Win", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, the case was filed by Strive Specialties, which claimed the drugmakers unfairly limited access to compounded GLP-1 weight-loss drugs through exclusive telehealth partnerships. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-rises-glp-195231835.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:52:31+00:00", "published_display": "07 Aug 2026 19:52", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.239, "duplicate_count": 1, "topics": ["Antitrust", "Lawsuit", "Obesity Drugs", "Pharma"]}, {"title": "Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound", "summary": "Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer \u203a The past few years have been rough on Pfizer(NYSE: PFE). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster pro", "url": "https://www.nasdaq.com/articles/pfizers-next-weight-loss-weapon-how-berobenatide-stacks-against-novo-nordisks-wegovy-and", "source_name": "nasdaq.com", "published_at": "2026-08-07T19:48:00+00:00", "published_display": "07 Aug 2026 19:48", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.208, "duplicate_count": 1, "topics": ["Clinical Trials", "Dividends", "Financial Results", "Markets", "Pharmaceuticals", "Share Price"]}], "by_tier": {"direct": [{"title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:29:11+00:00", "published_display": "12 Aug 2026 17:29", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.389, "duplicate_count": 1, "topics": ["Downgrade", "Earnings", "Pharma"]}, {"title": "European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading", "summary": "European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:11:23+00:00", "published_display": "12 Aug 2026 15:11", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.382, "duplicate_count": 1, "topics": []}, {"title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "summary": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:10:00+00:00", "published_display": "12 Aug 2026 15:10", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.478, "duplicate_count": 1, "topics": ["Diabetes", "Earnings", "Fourth Quarter", "Guidance", "Obesity", "Pharma"]}, {"title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "summary": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T15:03:00+00:00", "published_display": "12 Aug 2026 15:03", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.263, "duplicate_count": 1, "topics": ["Earnings", "Guidance", "Obesity", "Oncology", "Pharma", "Revenue Growth"]}, {"title": "Here Are Wednesday\u2019s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More", "summary": "Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price index will be released at the same time tomorrow. Economists forecast headline CPI to rise 0.1% month-over-month and 3.4% year-over-year, with core CPI expected to increase 0.2% month-over-month and 2.5% year-over-year. One thing is for sure; if the numbers come in hot and above expectations, the stock market could see a bout of heavy selling. All of the major ind", "url": "https://finance.yahoo.com/markets/stocks/articles/wednesday-top-wall-street-analyst-115341914.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T11:53:41+00:00", "published_display": "12 Aug 2026 11:53", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.373, "duplicate_count": 1, "topics": ["Crypto", "Earnings", "Price Target", "Price Target", "Upgrade Downgrade"]}, {"title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. ", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T19:07:32+00:00", "published_display": "11 Aug 2026 19:07", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.475, "duplicate_count": 1, "topics": ["Fda Approval", "Obesity", "Pharma", "Regulation"]}, {"title": "European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading", "summary": "European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/stocks/articles/european-equities-traded-us-american-152616420.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:26:16+00:00", "published_display": "11 Aug 2026 15:26", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.322, "duplicate_count": 1, "topics": []}, {"title": "Lilly Takes Its Weight-Loss Pill Battle Overseas", "summary": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo", "url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T15:12:41+00:00", "published_display": "11 Aug 2026 15:12", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 57, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.462, "duplicate_count": 1, "topics": ["Fda Approval", "Healthcare", "Pharma", "UK Approval"]}, {"title": "Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?", "summary": "The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trial", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:44:16+00:00", "published_display": "11 Aug 2026 12:44", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.454, "duplicate_count": 1, "topics": ["Clinical Trials", "Financial Results", "Lawsuit", "Net Income", "Obesity Treatment", "Pharma"]}, {"title": "Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery", "summary": "Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica", "url": "https://finance.yahoo.com/healthcare/articles/cloud-ai-today-novo-nordisk-123802779.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-11T12:38:02+00:00", "published_display": "11 Aug 2026 12:38", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 47, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.241, "duplicate_count": 1, "topics": ["AI", "Cloud", "Earnings"]}, {"title": "NVO Crosses Above Average Analyst Target", "summary": "In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst ", "url": "https://www.nasdaq.com/articles/nvo-crosses-above-average-analyst-target-0", "source_name": "nasdaq.com", "published_at": "2026-08-11T11:43:35+00:00", "published_display": "11 Aug 2026 11:43", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.314, "duplicate_count": 1, "topics": ["Etfs", "Markets", "Price Target", "Price Target", "Ratings", "Stocks"]}, {"title": "Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America\u2019s New Drug Manufacturing Policies?", "summary": "For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and suppl", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-222158536.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T22:21:58+00:00", "published_display": "10 Aug 2026 22:21", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.356, "duplicate_count": 1, "topics": ["Fda", "Manufacturing", "Obesity Drugs", "Pharma", "Revenue Growth", "Shareholder"]}, {"title": "Why Eli Lilly Topped the Market Today", "summary": "Key Points This market has a population of almost 60 million. While the drug isn't the first of its type to be sold in that country, it will have Lilly's considerable marketing power behind it.10 stocks we like better than Eli Lilly \u203a Eli Lilly(NYSE: LLY) had a fine start to the trading week. On Monday, its stock rose by almost 4% on news that a key European regulator had approved one of its star medications. That also provided plenty of optimism for these types of drugs, which have been hotly popular for years now. The popular pill The product in question is Lilly's Foundayo, its first weight", "url": "https://www.nasdaq.com/articles/why-eli-lilly-topped-market-today", "source_name": "nasdaq.com", "published_at": "2026-08-10T22:13:52+00:00", "published_display": "10 Aug 2026 22:13", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 54, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.25, "duplicate_count": 1, "topics": ["Europe", "Markets", "Obesity Treatments", "Pharma", "Regulation"]}, {"title": "Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?", "summary": "The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthro", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-213923809.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T21:39:23+00:00", "published_display": "10 Aug 2026 21:39", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 67, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.23, "duplicate_count": 1, "topics": ["Manufacturing", "Obesity Market", "Pharma"]}, {"title": "Hims Stock Falls on Earnings. Why a Guidance Hike Isn\u2019t Enough.", "summary": "Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading", "url": "https://finance.yahoo.com/m/db700a16-f71a-30fb-9e7e-c325c0d84078/hims-stock-falls-on-earnings..html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T21:12:00+00:00", "published_display": "10 Aug 2026 21:12", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.353, "duplicate_count": 1, "topics": ["Healthcare", "Restructuring"]}, {"title": "Eli Lilly Stock Rises 2.1% as UK Clears Obesity Pill", "summary": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) just added another weapon to its obesity arsenal. The pharmaceutical giant received British authorization for Foundayo on Monday, making the U.K. the first European country to clear the once-daily orforglipron tablet for weight management and type 2 diabetes. Lilly shares rose approximately 2.1% in regular trading. The appeal is easy to understand: no injection. Foundayo targets GLP-1 while giving patients an oral alternative to Lilly's blockbuster Mounjaro and Zepbound. The pill entered the U.S. market in April and generated $98 m", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-stock-rises-2-193507373.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T19:35:07+00:00", "published_display": "10 Aug 2026 19:35", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 46, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.213, "duplicate_count": 1, "topics": ["Fda Approval", "Glp 1", "Obesity", "Pharma", "Revenue Outlook"]}, {"title": "European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments", "summary": "The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "url": "https://finance.yahoo.com/markets/stocks/articles/european-stocks-close-mixed-monday-153834840.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T15:38:34+00:00", "published_display": "10 Aug 2026 15:38", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.271, "duplicate_count": 1, "topics": []}, {"title": "This Biotech\u2019s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.", "summary": "New data show a single dose of AbCellera\u2019s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading", "url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T14:12:00+00:00", "published_display": "10 Aug 2026 14:12", "provider": "eodhd", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.133, "duplicate_count": 1, "topics": []}, {"title": "Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock", "summary": "Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-rises-almost-7-post-131700150.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T13:17:00+00:00", "published_display": "10 Aug 2026 13:17", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.333, "duplicate_count": 1, "topics": ["Earnings", "Earnings Growth", "Earnings Per Share", "Obesity", "Oncology", "Patent Cliff"]}, {"title": "Is new time to buy weakness in Novo Nordisk stock? Bernstein answers", "summary": "", "url": "", "source_name": "Investing.com", "published_at": "2026-08-10T10:46:21+00:00", "published_display": "10 Aug 2026 10:46", "provider": "", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.178, "duplicate_count": 1, "topics": []}, {"title": "Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress", "summary": "Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients \u2013 -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 -- -- Company to host conference call and webcast t", "url": "https://finance.yahoo.com/healthcare/articles/veru-reports-fiscal-2026-third-103000378.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T10:30:00+00:00", "published_display": "10 Aug 2026 10:30", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.327, "duplicate_count": 1, "topics": ["Biopharmaceuticals", "Clinical Trials", "Financial Results", "Fourth Quarter", "Obesity", "Operating Income"]}, {"title": "Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date", "summary": "(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-holding-says-apitegromab-091940105.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T09:19:40+00:00", "published_display": "10 Aug 2026 09:19", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.259, "duplicate_count": 1, "topics": ["Biotech", "Fda Approval"]}, {"title": "Nvidia, Eli Lilly, and Disney Show It\u2019s Time to Back the Top Dogs", "summary": "Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading", "url": "https://finance.yahoo.com/m/bd14b29c-18a2-3bb0-930e-e50923390400/nvidia%2C-eli-lilly%2C-and-disney.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T05:00:00+00:00", "published_display": "10 Aug 2026 05:00", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.204, "duplicate_count": 1, "topics": []}, {"title": "Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients", "summary": "Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing, while providing home delivery and in-store pickup to streamline access. Amazon Pharmacy will begin enrollment for eligible patients after they add their insurance and Medicare information and their clinician ", "url": "https://finance.yahoo.com/healthcare/articles/ozempic-50-month-amazon-pharmacy-013108263.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-10T01:31:08+00:00", "published_display": "10 Aug 2026 01:31", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 35, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.306, "duplicate_count": 1, "topics": ["Digital Healthcare", "Pharmacy", "Real Estate", "Weight Loss"]}, {"title": "Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Pfizer in focus", "summary": "Wall Street\u2019s major market averages ended higher on Friday after July's nonfarm payrolls surprised to the downside, showing an unexpected contraction in employment. The blue-chip Dow edged up 0.3%, the benchmark S&P 500 gained 0.62%, and the tech-focused Nasdaq Composite jumped 1.3%. The S&P 500 Health Care Index Sector (XLV [https://seekingalpha.com/symbol/XLV]) gained 1.92% during the week. The top S&P 500 healthcare gainers and losers for the last week are as follows: TOP GAINERS: Charles River Laboratories International (CRL [https://seekingalpha.com/symbol/CRL]) +15.04% Veeva Systems (VEE", "url": "https://seekingalpha.com/news/4629554-notable-healthcare-headlines-for-the-week-eli-lilly-novo-nordisk-and-pfizer-in-focus?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:05:04+00:00", "published_display": "09 Aug 2026 13:05", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 43, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.28, "duplicate_count": 1, "topics": ["Consensus Estimate", "Earnings", "Earnings Per Share", "Guidance", "Healthcare", "M A"]}, {"title": "Top global stories this week: BP, SoftBank among notable names", "summary": "US stock indexes ended the week higher supported by a rally in mega-cap technology stocks, a rebound in Treasury securities and robust corporate earnings. By the end of the week, geopolitical tensions involving Iran pushed crude oil prices toward $78 per barrel, raising fears that higher energy costs could stoke inflation and delay central bank rate cuts. For the week, the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) rose 3% and 3.9%, while Dow (DJI [https://seekingalpha.com/symbol/DJI]) booked a 1.8% uptick. Across th", "url": "https://seekingalpha.com/news/4629627-top-global-stories-this-week-bp-softbank-among-notable-names?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-09T13:00:00+00:00", "published_display": "09 Aug 2026 13:00", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.252, "duplicate_count": 1, "topics": ["Acquisition", "Earnings", "Earnings News", "Guidance", "On The Move", "Semiconductors"]}, {"title": "Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray", "summary": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-231020183.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T23:10:20+00:00", "published_display": "08 Aug 2026 23:10", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.165, "duplicate_count": 1, "topics": ["Balance Sheet", "Healthcare", "Patent Enforcement", "Pharma", "Share Price"]}, {"title": "Novo Nordisk A/S Q2 Earnings Call Highlights", "summary": "Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-q2-earnings-call-220350961.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T22:03:50+00:00", "published_display": "08 Aug 2026 22:03", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.251, "duplicate_count": 1, "topics": ["Cardiovascular", "Diabetes", "Earnings", "Obesity", "Pharmaceuticals"]}, {"title": "BofA points to the Eli Lilly market that could outsize the U.S.", "summary": "Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came out of the earnings call pointing to a different number. The bank thinks the obesity market outside the United States could eventually surpass U.S. sales of the same drugs. For anyone holding LLY or considering it, that international call is worth a closer look. Why Bank of America raised its Eli Lill", "url": "https://finance.yahoo.com/healthcare/articles/bofa-points-eli-lilly-market-183300957.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-08T18:33:00+00:00", "published_display": "08 Aug 2026 18:33", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.245, "duplicate_count": 1, "topics": ["Drug Development", "Earnings", "Earnings Estimate", "Obesity", "Pharma", "Price Target"]}, {"title": "Trending stocks this week as SpaceX, Palantir earnings and jobs data drive markets", "summary": "[Wall Street New York stock exchange stock market] alexsl Wall Street ended the week higher, with the Dow Jones Industrial Average (DJI [https://seekingalpha.com/symbol/DJI]) and the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) closing at record highs as investors weighed a deluge of corporate earnings, including results from SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) and Palantir Technologies (PLTR [https://seekingalpha.com/symbol/PLTR]), alongside weaker-than-expected U.S. payrolls data. U.S. nonfarm payrolls fell by 23,000 in July, missing economists' expectations for a", "url": "https://seekingalpha.com/news/4629310-trending-stocks-this-week-as-spacex-palantir-earnings-and-jobs-data-drive-markets?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_name": "seekingalpha.com", "published_at": "2026-08-08T17:12:36+00:00", "published_display": "08 Aug 2026 17:12", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 85, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.242, "duplicate_count": 1, "topics": ["AI", "Consensus Estimate", "Earnings", "Earnings Per Share", "Earnings Report", "Fourth Quarter"]}, {"title": "Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem", "summary": "Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first quarter of 2027. This new product could help Eli Lilly extend its lead over its biggest competitor in this space, Novo Nordisk (NYSE: NVO). Here's the rundown. Best-in-class efficacy In a phase 3 study, retatrutide posted an average ", "url": "https://finance.yahoo.com/healthcare/articles/eli-lillys-timing-fda-filing-225000821.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T22:50:00+00:00", "published_display": "07 Aug 2026 22:50", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.212, "duplicate_count": 1, "topics": ["Clinical Trials", "Earnings", "Earnings Per Share", "Fda Approval", "Financial Results", "Pharma"]}, {"title": "Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date", "summary": "Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and under their guidance, will remove Catalent Indiana fill-finish facility from apitegromab BLA FDA review of second fill-finish facility progressing; Data package for FDA review of second fill-finish facility, as agreed to during March 2026 Type C meeting, has been submitted in advance of agreed up", "url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-announces-fda-review-202000956.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T20:20:00+00:00", "published_display": "07 Aug 2026 20:20", "provider": "eodhd", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.25, "duplicate_count": 1, "topics": ["Biotech", "Clinical Trials", "Fda Approval", "Press Releases", "Rare Diseases", "Spinal Muscular Atrophy"]}, {"title": "Novo Nordisk Stock Rises After GLP-1 Antitrust Win", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, the case was filed by Strive Specialties, which claimed the drugmakers unfairly limited access to compounded GLP-1 weight-loss drugs through exclusive telehealth partnerships. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-rises-glp-195231835.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-07T19:52:31+00:00", "published_display": "07 Aug 2026 19:52", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 33, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.239, "duplicate_count": 1, "topics": ["Antitrust", "Lawsuit", "Obesity Drugs", "Pharma"]}, {"title": "Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound", "summary": "Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer \u203a The past few years have been rough on Pfizer(NYSE: PFE). The company has generally posted subpar financial results due to weakness within its coronavirus franchise, which once helped it become the first biopharmaceutical company to achieve $100 billion in annual sales. The drugmaker is looking to turn things around by developing potential blockbuster pro", "url": "https://www.nasdaq.com/articles/pfizers-next-weight-loss-weapon-how-berobenatide-stacks-against-novo-nordisks-wegovy-and", "source_name": "nasdaq.com", "published_at": "2026-08-07T19:48:00+00:00", "published_display": "07 Aug 2026 19:48", "provider": "eodhd", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.208, "duplicate_count": 1, "topics": ["Clinical Trials", "Dividends", "Financial Results", "Markets", "Pharmaceuticals", "Share Price"]}], "industry": [], "sector": []}, "total_fetched": 34, "total_unique": 34, "total_relevant": 34, "pipeline_health": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 33}, "raw_articles": 33, "unique_stories": 33, "duplicates_removed": 0, "relevant_stories": 34, "current_evidence": 34, "direct_evidence": 34, "eodhd_articles": 33, "eodhd": {"configured": true, "status": "healthy", "calls_used": 245, "call_budget": 500, "budget_used_pct": 49.0, "requests_made": 49, "last_success_at": "2026-08-13T08:01:29.952746+00:00", "newest_seen_at": "2026-08-13T07:52:03+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3285, "unmapped_mentions": 1825}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-12T08:58:29.810645+00:00", "durable_newest_article_at": "2026-08-10T10:46:21+00:00", "durable_story_count": 1}, "sentiment_summary": {"positive": 16, "negative": 12, "neutral": 6, "score": 53, "raw_score": 53, "total": 34, "evidence_count": 34, "effective_articles": 31.14, "direct_story_count": 34, "industry_story_count": 0, "sector_story_count": 0, "story_count": 34, "source_count": 4, "source_concentration": 0.695, "direct_share": 100, "dispersion": 18, "confidence": 84, "evidence_status": "measured", "score_version": "evidence-v4", "newest_article_at": "2026-08-12T17:29:11+00:00", "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 74, "events": [{"event": "earnings", "label": "Earnings", "weight": 8.4, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 4.2, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.0, "count": 5}, {"event": "general", "label": "Market update", "weight": 2.62, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.2, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.6, "count": 1}], "positive_events": 16, "negative_events": 12, "pipeline": {"providers_attempted": 1, "providers_with_results": 1, "provider_counts": {"eodhd": 33}, "raw_articles": 33, "unique_stories": 33, "duplicates_removed": 0, "relevant_stories": 34, "current_evidence": 34, "direct_evidence": 34, "eodhd_articles": 33, "eodhd": {"configured": true, "status": "healthy", "calls_used": 245, "call_budget": 500, "budget_used_pct": 49.0, "requests_made": 49, "last_success_at": "2026-08-13T08:01:29.952746+00:00", "newest_seen_at": "2026-08-13T07:52:03+00:00", "rate_limit": 1200, "rate_remaining": 1199, "last_error": "", "mapped_mentions": 3285, "unmapped_mentions": 1825}, "status": "healthy", "durable_evidence_used": true, "durable_collected_at": "2026-08-12T08:58:29.810645+00:00", "durable_newest_article_at": "2026-08-10T10:46:21+00:00", "durable_story_count": 1}}, "market_context": {"has_market_context": true, "latest_close": 810.0, "latest_week": "2026-08-07", "one_week_move": -10.0, "four_week_move": -6.8, "twelve_week_move": -3.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.118541, "market_dynamics_buy_signal": false, "relative_strength": -10.973892, "fair_value_gap": -47.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 53.1212, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.0% over one week, -6.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 27}, {"label": "nasdaq.com", "count": 3}, {"label": "seekingalpha.com", "count": 3}, {"label": "Investing.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 34}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 5}, {"label": "Market update", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Evidence confidence", "value": "84/100", "tone": "positive", "text": "31.14 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "74/100 classification confidence."}, {"label": "Company focus", "value": "34", "tone": "positive", "text": "100% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "18/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.0% over one week, -6.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market"}], "updated_at": "2026-08-12T08:58:29.810645+00:00", "detail_intelligence": {"headline": "Price moving ahead of tone", "summary": "Balanced news tone is drawn from 34 fresh independent stories, including 34 company-specific items across 4 publishers.", "status": "measured", "metrics": [{"label": "Weighted tone", "value": 53, "display": "53", "tone": "neutral", "note": "Balanced news tone"}, {"label": "Evidence confidence", "value": 84, "display": "84", "tone": "positive", "note": "high confidence"}, {"label": "Company focus", "value": 100, "display": "100%", "tone": "positive", "note": "34 direct stories"}, {"label": "Evidence agreement", "value": 82, "display": "82", "tone": "positive", "note": "18/100 dispersion"}], "confidence_drivers": [{"label": "Sample depth", "value": 100, "note": "31.14 effective stories"}, {"label": "Source breadth", "value": 80, "note": "4 independent publishers"}, {"label": "Direct relevance", "value": 100, "note": "company-specific evidence share"}, {"label": "Freshness", "value": 66, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 82, "note": "cross-story consistency"}, {"label": "Source independence", "value": 31, "note": "lower publisher concentration"}], "freshness": 66, "source_independence": 31, "timeline": [{"date": "2026-07-24", "label": "24 Jul", "count": 0, "score": null, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-25", "label": "25 Jul", "count": 0, "score": null, "tone": "neutral", "x": 87.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-26", "label": "26 Jul", "count": 0, "score": null, "tone": "neutral", "x": 133.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-27", "label": "27 Jul", "count": 0, "score": null, "tone": "neutral", "x": 179.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-28", "label": "28 Jul", "count": 0, "score": null, "tone": "neutral", "x": 225.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-29", "label": "29 Jul", "count": 0, "score": null, "tone": "neutral", "x": 271.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-30", "label": "30 Jul", "count": 0, "score": null, "tone": "neutral", "x": 316.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-07-31", "label": "31 Jul", "count": 0, "score": null, "tone": "neutral", "x": 362.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-01", "label": "01 Aug", "count": 0, "score": null, "tone": "neutral", "x": 408.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-02", "label": "02 Aug", "count": 0, "score": null, "tone": "neutral", "x": 454.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-03", "label": "03 Aug", "count": 0, "score": null, "tone": "neutral", "x": 500.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-04", "label": "04 Aug", "count": 0, "score": null, "tone": "neutral", "x": 545.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-05", "label": "05 Aug", "count": 0, "score": null, "tone": "neutral", "x": 591.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-06", "label": "06 Aug", "count": 0, "score": null, "tone": "neutral", "x": 637.4, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-08-07", "label": "07 Aug", "count": 4, "score": 53, "tone": "neutral", "x": 683.2, "y": 129.5, "volume_height": 16.0, "volume_y": 250.0}, {"date": "2026-08-08", "label": "08 Aug", "count": 4, "score": 67, "tone": "positive", "x": 729.0, "y": 104.1, "volume_height": 16.0, "volume_y": 250.0}, {"date": "2026-08-09", "label": "09 Aug", "count": 2, "score": 37, "tone": "negative", "x": 774.8, "y": 158.7, "volume_height": 8.0, "volume_y": 258.0}, {"date": "2026-08-10", "label": "10 Aug", "count": 13, "score": 48, "tone": "neutral", "x": 820.6, "y": 138.6, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-08-11", "label": "11 Aug", "count": 6, "score": 58, "tone": "positive", "x": 866.4, "y": 120.4, "volume_height": 24.0, "volume_y": 242.0}, {"date": "2026-08-12", "label": "12 Aug", "count": 5, "score": 54, "tone": "neutral", "x": 912.2, "y": 127.7, "volume_height": 20.0, "volume_y": 246.0}, {"date": "2026-08-13", "label": "13 Aug", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "683.2,129.5 729.0,104.1 774.8,158.7 820.6,138.6 866.4,120.4 912.2,127.7", "timeline_has_signal": true, "timeline_start": "24 Jul", "timeline_mid": "03 Aug", "timeline_end": "13 Aug", "momentum": {"label": "Stable", "tone": "neutral", "recent_score": 53, "prior_score": 54, "delta": -1, "recent_count": 22, "prior_count": 12, "volume_delta": 10}, "freshness_buckets": [{"label": "Last 24 hours", "count": 5, "share": 15}, {"label": "1 to 3 days", "count": 17, "share": 50}, {"label": "4 to 7 days", "count": 12, "share": 35}, {"label": "8 to 30 days", "count": 0, "share": 0}], "source_profile": [{"label": "finance.yahoo.com", "count": 27, "share": 79, "score": 53, "tone": "neutral"}, {"label": "nasdaq.com", "count": 3, "share": 9, "score": 54, "tone": "neutral"}, {"label": "seekingalpha.com", "count": 3, "share": 9, "score": 52, "tone": "neutral"}, {"label": "Investing.com", "count": 1, "share": 3, "score": 50, "tone": "neutral"}], "event_profile": [{"label": "Earnings", "count": 14, "share": 41, "score": 49, "tone": "neutral"}, {"label": "Analyst action", "count": 7, "share": 21, "score": 58, "tone": "positive"}, {"label": "Regulatory and legal", "count": 5, "share": 15, "score": 52, "tone": "neutral"}, {"label": "Market update", "count": 4, "share": 12, "score": 60, "tone": "positive"}, {"label": "Deals and strategy", "count": 2, "share": 6, "score": 40, "tone": "negative"}, {"label": "Guidance", "count": 1, "share": 3, "score": 74, "tone": "positive"}, {"label": "Macro sensitivity", "count": 1, "share": 3, "score": 67, "tone": "positive"}], "topics": [{"label": "Pharma", "count": 14, "share": 41}, {"label": "Earnings", "count": 12, "share": 35}, {"label": "Obesity", "count": 8, "share": 24}, {"label": "Fda Approval", "count": 6, "share": 18}, {"label": "Price Target", "count": 5, "share": 15}, {"label": "Clinical Trials", "count": 5, "share": 15}, {"label": "Healthcare", "count": 4, "share": 12}, {"label": "Guidance", "count": 4, "share": 12}, {"label": "Financial Results", "count": 4, "share": 12}, {"label": "Earnings Per Share", "count": 4, "share": 12}], "supporting": [{"label": "Direct evidence", "text": "34 current stories are mapped specifically to NOVOBN."}, {"label": "Source breadth", "text": "The read spans 4 publishers rather than depending on one outlet."}, {"label": "Narrative agreement", "text": "Cross-story agreement is 82/100, indicating a comparatively coherent tape."}], "tempering": [{"label": "Price disagreement", "text": "Price is moving more forcefully than the current news tone suggests."}], "supporting_heading": "What supports the read", "tempering_heading": "What tempers the read", "latest_observation": {"title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "summary": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "source_name": "finance.yahoo.com", "published_at": "2026-08-12T17:29:11+00:00", "published_display": "12 Aug 2026 17:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.389, "duplicate_count": 1, "topics": ["Downgrade", "Earnings", "Pharma"]}, "article_count": 34, "updated_at": "2026-08-12T08:58:29.810645+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 73.4, "label": "13 Feb 2026", "close": 868.88, "index": 100.0}, {"x": 77.5, "y": 74.1, "label": "20 Feb 2026", "close": 867.63, "index": 99.9}, {"x": 113.1, "y": 204.2, "label": "27 Feb 2026", "close": 637.67, "index": 73.4}, {"x": 148.6, "y": 165.1, "label": "06 Mar 2026", "close": 706.75, "index": 81.3}, {"x": 184.2, "y": 184.1, "label": "13 Mar 2026", "close": 673.27, "index": 77.5}, {"x": 219.7, "y": 179.0, "label": "20 Mar 2026", "close": 682.16, "index": 78.5}, {"x": 255.3, "y": 173.4, "label": "27 Mar 2026", "close": 692.05, "index": 79.6}, {"x": 290.8, "y": 191.6, "label": "03 Apr 2026", "close": 660.0, "index": 76.0}, {"x": 326.4, "y": 177.1, "label": "10 Apr 2026", "close": 685.5, "index": 78.9}, {"x": 361.9, "y": 149.7, "label": "17 Apr 2026", "close": 734.0, "index": 84.5}, {"x": 397.5, "y": 168.9, "label": "24 Apr 2026", "close": 700.0, "index": 80.6}, {"x": 433.0, "y": 158.2, "label": "01 May 2026", "close": 719.0, "index": 82.8}, {"x": 468.6, "y": 112.4, "label": "08 May 2026", "close": 800.0, "index": 92.1}, {"x": 504.1, "y": 91.4, "label": "15 May 2026", "close": 837.0, "index": 96.3}, {"x": 539.7, "y": 122.6, "label": "22 May 2026", "close": 782.0, "index": 90.0}, {"x": 575.2, "y": 118.0, "label": "29 May 2026", "close": 790.0, "index": 90.9}, {"x": 610.8, "y": 146.9, "label": "05 Jun 2026", "close": 739.0, "index": 85.1}, {"x": 646.3, "y": 141.2, "label": "12 Jun 2026", "close": 749.0, "index": 86.2}, {"x": 681.9, "y": 129.3, "label": "19 Jun 2026", "close": 770.0, "index": 88.6}, {"x": 717.4, "y": 112.4, "label": "26 Jun 2026", "close": 800.0, "index": 92.1}, {"x": 753.0, "y": 84.1, "label": "03 Jul 2026", "close": 850.0, "index": 97.8}, {"x": 788.5, "y": 73.3, "label": "10 Jul 2026", "close": 869.0, "index": 100.0}, {"x": 824.1, "y": 59.2, "label": "17 Jul 2026", "close": 894.0, "index": 102.9}, {"x": 859.6, "y": 61.0, "label": "24 Jul 2026", "close": 890.77, "index": 102.5}, {"x": 895.2, "y": 55.8, "label": "31 Jul 2026", "close": 899.99, "index": 103.6}, {"x": 930.7, "y": 106.7, "label": "07 Aug 2026", "close": 810.0, "index": 93.2}], "sentiment_points": [{"x": 711.0, "y": 139.2, "label": "24 Jun 2026", "score": 45}, {"x": 712.2, "y": 133.7, "label": "24 Jun 2026", "score": 48}, {"x": 716.3, "y": 131.8, "label": "25 Jun 2026", "score": 49}, {"x": 733.8, "y": 139.2, "label": "29 Jun 2026", "score": 45}, {"x": 735.1, "y": 137.4, "label": "29 Jun 2026", "score": 46}, {"x": 740.4, "y": 137.4, "label": "30 Jun 2026", "score": 46}, {"x": 745.2, "y": 135.5, "label": "01 Jul 2026", "score": 47}, {"x": 753.3, "y": 126.3, "label": "03 Jul 2026", "score": 52}, {"x": 755.8, "y": 120.8, "label": "03 Jul 2026", "score": 55}, {"x": 769.4, "y": 130.0, "label": "06 Jul 2026", "score": 50}, {"x": 773.8, "y": 133.7, "label": "07 Jul 2026", "score": 48}, {"x": 774.3, "y": 130.0, "label": "07 Jul 2026", "score": 50}, {"x": 780.8, "y": 131.8, "label": "08 Jul 2026", "score": 49}, {"x": 781.9, "y": 135.5, "label": "08 Jul 2026", "score": 47}, {"x": 781.9, "y": 135.5, "label": "08 Jul 2026", "score": 47}, {"x": 781.9, "y": 135.5, "label": "08 Jul 2026", "score": 47}, {"x": 785.8, "y": 135.5, "label": "09 Jul 2026", "score": 47}, {"x": 787.3, "y": 135.5, "label": "09 Jul 2026", "score": 47}, {"x": 790.7, "y": 131.8, "label": "10 Jul 2026", "score": 49}, {"x": 791.1, "y": 131.8, "label": "10 Jul 2026", "score": 49}, {"x": 800.1, "y": 135.5, "label": "12 Jul 2026", "score": 47}, {"x": 803.9, "y": 137.4, "label": "13 Jul 2026", "score": 46}, {"x": 804.9, "y": 137.4, "label": "13 Jul 2026", "score": 46}, {"x": 806.1, "y": 137.4, "label": "13 Jul 2026", "score": 46}, {"x": 811.6, "y": 137.4, "label": "14 Jul 2026", "score": 46}, {"x": 822.1, "y": 126.3, "label": "16 Jul 2026", "score": 52}, {"x": 826.4, "y": 135.5, "label": "17 Jul 2026", "score": 47}, {"x": 826.9, "y": 135.5, "label": "17 Jul 2026", "score": 47}, {"x": 832.0, "y": 142.9, "label": "18 Jul 2026", "score": 43}, {"x": 840.5, "y": 141.0, "label": "20 Jul 2026", "score": 44}, {"x": 842.0, "y": 144.7, "label": "20 Jul 2026", "score": 42}, {"x": 842.1, "y": 141.0, "label": "20 Jul 2026", "score": 44}, {"x": 842.5, "y": 141.0, "label": "20 Jul 2026", "score": 44}, {"x": 846.7, "y": 144.7, "label": "21 Jul 2026", "score": 42}, {"x": 849.7, "y": 139.2, "label": "22 Jul 2026", "score": 45}, {"x": 850.6, "y": 139.2, "label": "22 Jul 2026", "score": 45}, {"x": 856.5, "y": 141.0, "label": "23 Jul 2026", "score": 44}, {"x": 876.0, "y": 139.2, "label": "27 Jul 2026", "score": 45}, {"x": 880.5, "y": 139.2, "label": "28 Jul 2026", "score": 45}, {"x": 887.5, "y": 137.4, "label": "29 Jul 2026", "score": 46}, {"x": 887.5, "y": 137.4, "label": "29 Jul 2026", "score": 46}, {"x": 892.6, "y": 128.2, "label": "30 Jul 2026", "score": 51}, {"x": 892.8, "y": 126.3, "label": "30 Jul 2026", "score": 52}, {"x": 898.0, "y": 139.2, "label": "31 Jul 2026", "score": 45}, {"x": 902.9, "y": 135.5, "label": "01 Aug 2026", "score": 47}, {"x": 905.8, "y": 131.8, "label": "02 Aug 2026", "score": 49}, {"x": 911.6, "y": 126.3, "label": "03 Aug 2026", "score": 52}, {"x": 922.8, "y": 141.0, "label": "05 Aug 2026", "score": 44}, {"x": 935.5, "y": 137.4, "label": "07 Aug 2026", "score": 46}, {"x": 950.8, "y": 130.0, "label": "10 Aug 2026", "score": 50}, {"x": 952.3, "y": 130.0, "label": "11 Aug 2026", "score": 50}, {"x": 958.0, "y": 130.0, "label": "12 Aug 2026", "score": 50}], "price_path": "42.0,73.4 77.5,74.1 113.1,204.2 148.6,165.1 184.2,184.1 219.7,179.0 255.3,173.4 290.8,191.6 326.4,177.1 361.9,149.7 397.5,168.9 433.0,158.2 468.6,112.4 504.1,91.4 539.7,122.6 575.2,118.0 610.8,146.9 646.3,141.2 681.9,129.3 717.4,112.4 753.0,84.1 788.5,73.3 824.1,59.2 859.6,61.0 895.2,55.8 930.7,106.7", "sentiment_path": "711.0,139.2 712.2,133.7 716.3,131.8 733.8,139.2 735.1,137.4 740.4,137.4 745.2,135.5 753.3,126.3 755.8,120.8 769.4,130.0 773.8,133.7 774.3,130.0 780.8,131.8 781.9,135.5 781.9,135.5 781.9,135.5 785.8,135.5 787.3,135.5 790.7,131.8 791.1,131.8 800.1,135.5 803.9,137.4 804.9,137.4 806.1,137.4 811.6,137.4 822.1,126.3 826.4,135.5 826.9,135.5 832.0,142.9 840.5,141.0 842.0,144.7 842.1,141.0 842.5,141.0 846.7,144.7 849.7,139.2 850.6,139.2 856.5,141.0 876.0,139.2 880.5,139.2 887.5,137.4 887.5,137.4 892.6,128.2 892.8,126.3 898.0,139.2 902.9,135.5 905.8,131.8 911.6,126.3 922.8,141.0 935.5,137.4 950.8,130.0 952.3,130.0 958.0,130.0", "price_change": -6.8, "sentiment_change": 5, "latest_close": 810.0, "start_label": "13 Feb", "mid_label": "15 May", "end_label": "07 Aug"}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}